State of Alaska Department of Revenue Buys 1,115 Shares of Enovis Co. (NYSE:ENOV)

State of Alaska Department of Revenue increased its holdings in Enovis Co. (NYSE:ENOV) by 20.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,482 shares of the company’s stock after acquiring an additional 1,115 shares during the period. State of Alaska Department of Revenue’s holdings in Enovis were worth $279,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ENOV. American Century Companies Inc. raised its holdings in shares of Enovis by 78.6% in the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after acquiring an additional 665,208 shares during the last quarter. Magnetar Financial LLC increased its stake in Enovis by 66.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after buying an additional 442,051 shares during the last quarter. Diamond Hill Capital Management Inc. increased its stake in Enovis by 14.5% in the 2nd quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock valued at $125,929,000 after buying an additional 352,116 shares during the last quarter. Boston Partners increased its stake in Enovis by 206.5% in the 1st quarter. Boston Partners now owns 295,969 shares of the company’s stock valued at $18,455,000 after buying an additional 199,411 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in Enovis by 100.6% in the 1st quarter. Janus Henderson Group PLC now owns 378,020 shares of the company’s stock valued at $23,606,000 after buying an additional 189,584 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Down 3.0 %

Shares of ENOV stock opened at $46.42 on Friday. The company has a 50 day moving average of $42.23 and a 200-day moving average of $45.51. The company has a quick ratio of 1.08, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The firm has a market cap of $2.59 billion, a P/E ratio of -21.20 and a beta of 1.91.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.62 by $0.11. The company had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period last year, the firm earned $0.56 EPS. Sell-side analysts anticipate that Enovis Co. will post 2.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ENOV shares. Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday. JMP Securities started coverage on shares of Enovis in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective for the company. JPMorgan Chase & Co. decreased their price objective on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Finally, Evercore ISI decreased their price objective on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Enovis presently has an average rating of “Moderate Buy” and a consensus price target of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.